Report
EUR 12.76 For Business Accounts Only

POLYNOVO sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of POLYNOVO (AU), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 25, 2022, the closing price was AUD 1.26 and its target price was estimated at AUD 1.10.
Underlying
PolyNovo

Polynovo has two operating businesses, being PolyNovo Biomaterials Pty Ltd (PolyNovo) and Metabolic Pharmaceuticals Pty Ltd (Metabolic). PolyNovo is focused on developing its biodegradable polymer platform technology NovoSorb™ for medical products targeting reconstructive surgery and tissue repair. Metabolic owns the intellectual property around AOD9604 which is in development for the treatment of obesity, bone, cartilage and muscle diseases and repair.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch